Observational Epidemiological Study of disease progression and therapeutic approach in prostate Cancer Patients

Conditions

Prostate cancer Cancer

Cózar JM, Miñana B, Gómez-Veiga F, Rodríguez-Antolín A, Grupo Gescap.

2018-06-081 citations

10.1016/j.acuro.2018.03.004

Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study - GESCAP group.

Gómez-Veiga F, Rodríguez-Antolín A, Miñana B, Hernández C, Suárez JF, Fernández-Gómez JM, Unda M, Burgos J, Alcaraz A, Rodríguez P, Medina R, Castiñeiras J, Moreno C, Pedrosa E, Cózar JM, GESCAP.

2017-03-098 citations

10.1016/j.acuro.2016.10.009

Treatment trends for clinically localised prostate cancer. National population analysis: GESCAP group.

Miñana B, Rodríguez-Antolín A, Gómez-Veiga F, Hernández C, Suárez JF, Fernández-Gómez JM, Unda M, Burgos J, Alcaraz A, Rodríguez P, Moreno C, Pedrosa E, Cózar JM, Grupo Español de Cáncer de Próstata (GESCAP).

2015-12-237 citations

10.1016/j.acuro.2015.09.005

Interventions

This is an epidemiological, observational, multicentre, national study. A cohort of patients diagnosed with PCa in 2010 included in the ?Epidemiological study of the estimation of the incidence of PCa

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patient that was included in the study with code CaP01-10 with newly diagnosed, histopathologically confirmed PCa in any stage, between 1 January and 31 December 2010

Exclusion criteria

Exclusion criteria: Patients who have withdrawn their informed consent to take part in the study

Design outcomes

Primary

Measure	Time frame
1. Biochemical progression-free survival at 1, 2 and 3 years after being diagnosed in 2010 2. Clinical progression-free survival at 1, 2 and 3 years after being diagnosed in 2010	—

Secondary

Measure	Time frame
1. Patient?s clinical variables at the time of diagnosis associated with the 1 and 3 year survival 2. Therapeutic approach 3. Cancer-specific survival and overall survival	—

Countries

Spain

Outcome results

None listed